OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Inside the Clinic: JTCC Experts Highlight Key Takeaways from ASH 2021

March 7th 2022

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.

Inside the Clinic: JTCC Experts Highlight Pivotal Ongoing Trials in Multiple Myeloma

March 7th 2022

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss ongoing clinical trials in multiple myeloma.

Dr. Jeyarajah on SIR-Spheres® Y-90 Resin Microspheres as Maintenance in CRC With Liver Metastases

March 7th 2022

Rohan Jeyarajah, MD, discusses the potential role of SIR-Spheres® Y-90 resin microspheres from Sirtex Medical in colorectal cancer with liver metastases.

Dr. Borgen on the Immuno-Oncology Clinical Trials in Breast Cancer

March 4th 2022

Patrick Borgen, MD, discusses the evolution of immuno-oncology clinical trials in breast cancer.

Dr. Tripathy on the Emergence of Genomics Research in Breast Cancer

March 4th 2022

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

Dr. Hurvitz on Utilizing CDK4/6 Inhibitors in HR+ Breast Cancer

March 4th 2022

Sara A. Hurvitz, MD, discusses utilizing CDK4/6 inhibitors in hormone receptor-positive breast cancer.

Dr. Tolaney on Potential of Trastuzumab Deruxtecan to Shift to First Line in HER2+ Breast Cancer

March 4th 2022

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

Dr. Jagannath on the FDA Approval of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

March 3rd 2022

Sundar Jagannath, MBBS, discusses the FDA approval of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Westin on the Utilization of CAR T-Cell Therapy in LBCL

March 2nd 2022

Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Dr. Hong on Objectives of the CodeBreaK 101 Trial in CRC

March 2nd 2022

David S. Hong, MD, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial in mutated advanced colorectal cancer and other solid tumors harboring KRAS G12C mutations.

Dr. Choueiri on the Design of KEYNOTE-564 in RCC

March 2nd 2022

Toni Choueiri, MD, discusses the design of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Dr. Eroglu on the Utilization of ctDNA in Melanoma

March 1st 2022

Zeynep Eroglu, MD, discusses the utilization of circulating tumor DNA in patients with melanoma.

Dr. Traina on Results of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 1st 2022

Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Iams on the Key Implications of the ADAURA Trial in NSCLC

March 1st 2022

Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.

Dr. Burger on the Current Landscape of CAR T-Cell Therapy in CLL

March 1st 2022

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Mesa on the FDA Approval of Pacritinib in Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Dr. Kopetz on the Utilization of ctDNA in CRC

March 1st 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the utilization of circulating tumor DNA in colorectal cancer.

Dr. Wang on Adverse Effects of BTK Inhibitors in MCL

March 1st 2022

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

Dr. Iacovelli on the Rationale of the ARIES Trial in Urothelial Cancer

February 25th 2022

Roberto Iacovelli, MD, PhD, discusses the rationale of the phase 2 ARIES trial in urothelial cancer.

Dr. Raghav on the Utilization of ctDNA in mCRC

February 25th 2022

Kanwal P.S. Raghav, MBBS, MD, discusses on the utilization of circulating tumor DNA in metastatic colorectal cancer.